News >

Novel Antibody-Based Approaches on Horizon in Multiple Myeloma

Jessica Hergert
Published: Friday, Aug 30, 2019

Hearn Jay Cho, MD, PhD, an associate professor of medicine, hematology and medical oncology at Mount Sinai Hospital

Hearn Jay Cho, MD, PhD

Emerging antibody-based approaches, such as antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapies are inducing promising response rates in patients with multiple myeloma, said Hearn Jay Cho, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication